The FDA has approved a first-ever gene therapy for Duchenne muscular dystrophy based in part on technology developed by UW Medicine/ISCRM Researchers Read More about FDA Approves Gene Therapy with ISCRM Origins
Julie Mathieu, PhD and Niclas Bengtsson, PhD have received prestigious awards from the John H. Tietze Foundation Trust that will help fuel promising research underway in their labs. Read More about Meet the 2023 Tietze Award Winners
In the Freedman Lab, knocking out primary cilia reveals insights about the role the organelles play in cell fate and disease development. Read More about Freedman Lab Explores the Role Cilia Play in Signaling, Cell Fate, and Disease Development
ISCRM researchers have developed a tool to selectively control the PRC2 complex – an epigenetic regulator that influences cell fate across multiple stages of development. That tool is a computer-designed protein binder engineered in partnership with the Institute for Protein Design (IPD). Read More about Regulating Cells With Designed Proteins
New data presented by ISCRM Director Chuck Murry suggests gene-editing may be the key to clearing a major hurdle for researchers hoping to remuscularize injured hearts with stem cell-derived cardiomyocytes Read More about Gene Editing May Help Address Arrhythmia Challenges in Heart Regeneration